David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery
2021 ASTRO Annual Meeting
David A. Palma, MD, PhD, of Ontario’s London Health Sciences Centre, discusses results of the ORATOR2 study, which compared two treatment options that could be de-escalated for patients with HPV-associated oropharyngeal squamous cell carcinoma: a lower-dose radiation approach (6 weeks instead of 7, often with chemotherapy) vs a transoral surgical approach (with low-dose radiation afterward, for 5 weeks) (Abstract LBA2).
The ASCO Post Staff
Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.
The ASCO Post Staff
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.
The ASCO Post Staff
Erin Murphy, MD, of Cleveland Clinic, discusses new data that show no apparent difference in cognitive performance up to 2 years post-treatment among adults with low-grade glioma who were treated with concurrent radiotherapy and temozolomide (Abstract 3258).
The ASCO Post Staff
Mark K. Buyyounouski, MD, MS, of Stanford University, discusses phase III results from the NRG Oncology GU003 trial, which showed that, post-prostatectomy, using fewer—but higher—doses of radiation does not appear to increase long-term side effects or reduce quality of life when compared with conventional radiation treatment (Abstract 3).
The ASCO Post Staff
Shauna Campbell, DO, of Cleveland Clinic, discusses results from her study that showed hypofractionated intensity-modulated radiation therapy (H-IMRT) in the definitive or postoperative treatment of head and neck cancers using ≥ 50 Gy in 20 fractions appears to be safe and well tolerated with modest toxicity. Dr. Campbell suggests that prospective studies comparing the safety and efficacy of H-IMRT with those of conventionally fractionated IMRT are warranted (Abstract 2313).
